Global
Parkinson's
Disease Drug Market is expected
to grow at a significant CAGR in the upcoming years as the scope and its
applications are rising enormously across the globe. Parkinson’s disease (PD)
is termed as a neurodegenerative disorder that affects dopaminergic neurons in
a precise area of the brain called substantia nigra. Medicines are the most
common treatment for Parkinson’s disease. There are numerous drugs available to
treat both motor and non-motor symptoms of Parkinson ’s disease and all are
directed at easing symptoms and improving quality of life.

The
factors that are playing a major role in the growth of Parkinson's Disease Drug
Market are rising life expectancy, rising funding support & research
grants, growing healthcare expenditure, and rising awareness. In addition,
growing old age population and rising incidences of neurodegenerative diseases
are the other factors driving the industry. On the other hand, the high cost of
treatment, lack of expertise, and side effects of drugs are the factors
restraining overall market growth.
Parkinson's
Disease Drug Market is segmented based on drug types, distribution channel, end
users, applications, and region. Drug types such as Anticholinergics
(Benztropine or Trihexyphenidyl), Levodopa/Carbidopa, COMT-Inhibitors
(Entacapone, Tolcapone), Amantadine, Dopamine Agonists (Ropinirole or
Pramipexole), MAO-B Inhibitors (Selegiline, Rasagiline), Apomorphine, and
others classify this market.
Distribution
channels such as Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, and
others classify Parkinson's Disease Drug Market. End users such as Clinics,
Hospitals, and others classify this industry. Applications into Above 65 Years
Old, 40-65 Years Old, and Under 40 Years Old classify Parkinson's Disease Drug
Industry. This Market is segmented geographically Americas (North America,
Latin America), Europe (Eastern Europe, Western Europe), Asia Pacific, Latin
America, Middle East and Africa.
Globally,
North America accounts for the largest market share of Parkinson's Disease Drug
Market and is estimated to lead the overall market in the upcoming years. The
reason being, developed healthcare infrastructure, use of enhanced technology,
developed R&D, and good reimbursement policies. Europe and Asia Pacific
follow suit. On the other hand, Europe accounts for the second largest market
share of this industry. This is mainly due to rising R&D efforts by the
prominent players.
Market segment:
Geographically, this report is segmented
into several key Regions, with production, consumption, revenue (million USD),
market share and growth rate of Parkinson's Disease Drug in these regions, from
2012 to 2022 (forecast), covering
•
North America
•
Europe
•
China
•
Japan
•
Southeast Asia
•
India
Global Parkinson's Disease Drug market
competition by top manufacturers, with production, price, revenue (value) and
market share for each manufacturer; the top players including
•
Merck
•
Akorn
•
GSK
•
Novartis
•
Boehringer Ingelheim
•
Teva Pharmaceutical
•
Abbvie
•
Kyowa Hakko Kirin Pharma
•
Astellas Pharma
•
Desitin Arzneimittel
•
Endo Pharmaceuticals
•
F.Hoffmann-La Roche
The
key players of Parkinson's Disease Drug Industry are Valeant Pharmaceuticals,
GSK, US WorldMeds, Novartis, StadaArzneimittel, BoehringerIngelheim, Orion,
Teva Pharmaceutical, Apokyn, Abbvie, Valeant, Merck, Lundbeck, Akorn,
Hoffmann-La Roche, Kyowa Hakko Kirin Pharma, Endo Pharmaceuticals, Astellas
Pharma, and DesitinArzneimittel. These players are concentrating on inorganic
growth to sustain themselves amongst fierce competition. As such, mergers,
acquisitions, and joint ventures are the need of the hour.
Comments
Post a Comment